| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | FGF-13, FHF-2, FGF13, FHF2, Fibroblast growth factor homologous factor 2A, Fibroblast growth factor 13A, FGF13A |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Synthetic peptide amino acids 2-18 (AAAIASSLIRQKRQARE) of human FHF2A. 100% identical to rat, 94% identical to mouse. >80% identity with FGF12A/FHF1A, FGF14A/FHF4A and FGF11A/FHF3A. |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Fibroblast growth factor 13 (FGF13) is a non-secreted member of the FGF family that functions intracellularly to regulate neuronal excitability, microtubule stabilization, and axonal development. Unlike classical FGFs, FGF13 does not act through FGF receptors but instead modulates ion channel activity and cytoskeletal dynamics.
In the central nervous system, FGF13 is essential for proper neuronal migration and synaptic function. Mutations or altered expression of FGF13 have been linked to epilepsy, intellectual disability, and neurodevelopmental disorders. Recent studies suggest that FGF13 may also play a role in neurodegenerative diseases by influencing axonal transport and mitochondrial dynamics—processes disrupted in Alzheimer’s and ALS.
FGF13’s unique intracellular functions make it a compelling candidate for targeted therapies aimed at preserving neuronal integrity and function in neurodegenerative conditions.
1 µg/ml of SMC-448 was sufficient for detection of FHF2A (FGF13) in 20 µg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-448D — Size: 100 ug: FHF2A (FGF13) Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-448D, RRID: AB_2701811)
- SMC-448D-A390 — Size: 100 ug: FHF2A (FGF13) Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-448D-A390, RRID: AB_2701812)
- SMC-448D-A488 — Size: 100 ug: FHF2A (FGF13) Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-448D-A488, RRID: AB_2701813)
- SMC-448D-A594 — Size: 100 ug: FHF2A (FGF13) Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-448D-A594, RRID: AB_2701815)
- SMC-448D-APC — Size: 100 ug: FHF2A (FGF13) Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-448D-APC, RRID: AB_2701821)
- SMC-448D-BI — Size: 100 ug: FHF2A (FGF13) Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-448D-BI, RRID: AB_2701822)
- SMC-448D-FITC — Size: 100 ug: FHF2A (FGF13) Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-448D-FITC, RRID: AB_2701823)
- SMC-448D-HRP — Size: 100 ug: FHF2A (FGF13) Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-448D-HRP, RRID: AB_2701824)
- SMC-448D-PCP — Size: 100 ug: FHF2A (FGF13) Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-448D-PCP, RRID: AB_2701826)
- SMC-448D-RPE — Size: 100 ug: FHF2A (FGF13) Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-448D-RPE, RRID: AB_2701827)
- SMC-448S — Size: 12 ug: FHF2A (FGF13) Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-448S, RRID: AB_2701811)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Smallwood, P. M., et al. (1996) Proc. Nat. Acad. Sci. 93: 9850-9857.
